Vascular progenitors generated from tankyrase inhibitor-regulated naïve diabetic human iPSC potentiate efficient revascularization of ischemic retina.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
05 03 2020
Historique:
received: 20 06 2019
accepted: 28 01 2020
entrez: 7 3 2020
pubmed: 7 3 2020
medline: 24 6 2020
Statut: epublish

Résumé

Here, we report that the functionality of vascular progenitors (VP) generated from normal and disease-primed conventional human induced pluripotent stem cells (hiPSC) can be significantly improved by reversion to a tankyrase inhibitor-regulated human naïve epiblast-like pluripotent state. Naïve diabetic vascular progenitors (N-DVP) differentiated from patient-specific naïve diabetic hiPSC (N-DhiPSC) possessed higher vascular functionality, maintained greater genomic stability, harbored decreased lineage-primed gene expression, and were more efficient in migrating to and re-vascularizing the deep neural layers of the ischemic retina than isogenic diabetic vascular progenitors (DVP). These findings suggest that reprogramming to a stable naïve human pluripotent stem cell state may effectively erase dysfunctional epigenetic donor cell memory or disease-associated aberrations in patient-specific hiPSC. More broadly, tankyrase inhibitor-regulated naïve hiPSC (N-hiPSC) represent a class of human stem cells with high epigenetic plasticity, improved multi-lineage functionality, and potentially high impact for regenerative medicine.

Identifiants

pubmed: 32139672
doi: 10.1038/s41467-020-14764-5
pii: 10.1038/s41467-020-14764-5
pmc: PMC7058090
doi:

Substances chimiques

Enzyme Inhibitors 0
Poly(ADP-ribose) Polymerase Inhibitors 0
Tankyrases EC 2.4.2.30

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

1195

Subventions

Organisme : NICHD NIH HHS
ID : R01 HD082098
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL099775
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY009357
Pays : United States
Organisme : NHLBI NIH HHS
ID : R03 HL096220
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY023962
Pays : United States

Références

Lutty, G. A. Diabetic choroidopathy. Vis. Res. 139, 161–167 (2017).
pubmed: 28535994 doi: 10.1016/j.visres.2017.04.011
Zheng, L., Gong, B., Hatala, D. A. & Kern, T. S. Retinal ischemia and reperfusion causes capillary degeneration: similarities to diabetes. Invest. Ophthalmol. Vis. Sci. 48, 361–367 (2007).
pubmed: 17197555 doi: 10.1167/iovs.06-0510
Joussen, A. M. et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 18, 1450–1452 (2004).
pubmed: 15231732 doi: 10.1096/fj.03-1476fje
Joussen, A. M. et al. Leukocyte-mediated endothelial cell injury and death in the diabetic retina. Am. J. Pathol. 158, 147–152 (2001).
pubmed: 11141487 pmcid: 1850259 doi: 10.1016/S0002-9440(10)63952-1
D'Amore, P. A. Mechanisms of retinal and choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 35, 3974–3979 (1994).
pubmed: 7525506
Glaser, B. M., D'Amore, P. A., Michels, R. G., Patz, A. & Fenselau, A. Demonstration of vasoproliferative activity from mammalian retina. J. Cell Biol. 84, 298–304 (1980).
pubmed: 6155381 doi: 10.1083/jcb.84.2.298
Park, T. S. et al. Vascular progenitors from cord blood-derived induced pluripotent stem cells possess augmented capacity for regenerating ischemic retinal vasculature. Circulation 129, 359–372 (2014).
pubmed: 24163065 doi: 10.1161/CIRCULATIONAHA.113.003000
Dar, A. et al. Multipotent vasculogenic pericytes from human pluripotent stem cells promote recovery of murine ischemic limb. Circulation 125, 87–99 (2012).
pubmed: 22095829 doi: 10.1161/CIRCULATIONAHA.111.048264
Mandai, M., Kurimoto, Y. & Takahashi, M. Autologous induced stem-cell-derived retinal cells for macular degeneration. N. Engl. J. Med. 377, 792–793 (2017).
pubmed: 28834478 doi: 10.1056/NEJMc1706274
Sharma, R. et al. Clinical-grade stem cell-derived retinal pigment epithelium patch rescues retinal degeneration in rodents and pigs. Sci. Transl. Med. https://doi.org/10.1126/scitranslmed.aat5580 (2019).
pubmed: 30651323 doi: 10.1126/scitranslmed.aat5580
Zimmerlin, L., Park, T. S. & Zambidis, E. T. Capturing human naive pluripotency in the embryo and in the dish. Stem Cells Dev. 26, 1141–1161 (2017).
pubmed: 28537488 pmcid: 5564037 doi: 10.1089/scd.2017.0055
Zimmerlin, L. et al. Tankyrase inhibition promotes a stable human naive pluripotent state with improved functionality. Development 143, 4368–4380 (2016).
pubmed: 27660325 pmcid: 5201042 doi: 10.1242/dev.138982
Park, T. S., Zimmerlin, L., Evans-Moses, R. & Zambidis, E. T. Chemical reversion of conventional human pluripotent stem cells to a naive-like state with improved multilineage differentiation potency. J. Vis. Exp. https://doi.org/10.3791/57921 (2018).
Brunner, S. et al. Circulating angiopoietic cells and diabetic retinopathy in type 2 diabetes mellitus, with or without macrovascular disease. Invest. Ophthalmol. Vis. Sci. 52, 4655–4662 (2011).
pubmed: 21398276 doi: 10.1167/iovs.10-6520
Caballero, S. et al. Ischemic vascular damage can be repaired by healthy, but not diabetic, endothelial progenitor cells. Diabetes 56, 960–967 (2007).
pubmed: 17395742 pmcid: 3746188 doi: 10.2337/db06-1254
Jarajapu, Y. P. & Grant, M. B. The promise of cell-based therapies for diabetic complications: challenges and solutions. Circ. Res. 106, 854–869 (2010).
pubmed: 20299675 doi: 10.1161/CIRCRESAHA.109.213140
Khullar, M., Cheema, B. S. & Raut, S. K. Emerging evidence of epigenetic modifications in vascular complication of diabetes. Front. Endocrinol. (Lausanne) 8, 237 (2017).
doi: 10.3389/fendo.2017.00237
Manzar, G. S., Kim, E. M. & Zavazava, N. Demethylation of induced pluripotent stem cells from type 1 diabetic patients enhances differentiation into functional pancreatic beta cells. J. Biol. Chem. 292, 14066–14079 (2017).
pubmed: 28360105 pmcid: 5572901 doi: 10.1074/jbc.M117.784280
Theunissen, T. W. et al. Molecular criteria for defining the naive human pluripotent state. Cell Stem Cell 19, 502–515 (2016).
pubmed: 27424783 pmcid: 5065525 doi: 10.1016/j.stem.2016.06.011
Pastor, W. A. et al. Naive human pluripotent cells feature a methylation landscape devoid of blastocyst or germline memory. Cell Stem Cell 18, 323–329 (2016).
pubmed: 26853856 pmcid: 4779431 doi: 10.1016/j.stem.2016.01.019
Choi, J. et al. Prolonged Mek1/2 suppression impairs the developmental potential of embryonic stem cells. Nature 548, 219–223 (2017).
pubmed: 28746311 pmcid: 5905676 doi: 10.1038/nature23274
Yang, J. et al. Establishment of mouse expanded potential stem cells. Nature 550, 393–397 (2017).
pubmed: 29019987 pmcid: 5890884 doi: 10.1038/nature24052
Kim, H. et al. Modulation of beta-catenin function maintains mouse epiblast stem cell and human embryonic stem cell self-renewal. Nat. Commun. 4, 2403 (2013).
pubmed: 23985566 pmcid: 4183150 doi: 10.1038/ncomms3403
Gao, X. et al. Establishment of porcine and human expanded potential stem cells. Nat. Cell Biol. 21, 687–699 (2019).
pubmed: 31160711 pmcid: 7035105 doi: 10.1038/s41556-019-0333-2
Warrier, S. et al. Direct comparison of distinct naive pluripotent states in human embryonic stem cells. Nat. Commun. 8, 15055 (2017).
pubmed: 28429706 pmcid: 5413953 doi: 10.1038/ncomms15055
Lee, J. H. et al. Lineage-specific differentiation is influenced by state of human pluripotency. Cell Rep. 19, 20–35 (2017).
pubmed: 28380358 doi: 10.1016/j.celrep.2017.03.036
Park, T. S. et al. Growth factor-activated stem cell circuits and stromal signals cooperatively accelerate non-integrated iPSC reprogramming of human myeloid progenitors. PLoS One 7, e42838 (2012).
pubmed: 22905176 pmcid: 3414503 doi: 10.1371/journal.pone.0042838
Burridge, P. W. et al. A universal system for highly efficient cardiac differentiation of human induced pluripotent stem cells that eliminates interline variability. PLoS One 6, e18293 (2011).
pubmed: 21494607 pmcid: 3072973 doi: 10.1371/journal.pone.0018293
Bar-Nur, O. et al. Small molecules facilitate rapid and synchronous iPSC generation. Nat. Methods 11, 1170–1176 (2014).
pubmed: 25262205 pmcid: 4326224 doi: 10.1038/nmeth.3142
Pastor, W. A. et al. TFAP2C regulates transcription in human naive pluripotency by opening enhancers. Nat. Cell Biol. 20, 553–564 (2018).
pubmed: 29695788 pmcid: 5926822 doi: 10.1038/s41556-018-0089-0
Bai, P. Biology of poly(ADP-ribose) polymerases: the factotums of cell maintenance. Mol. Cell 58, 947–958, https://doi.org/10.1016/j.molcel.2015.01.034 (2015).
doi: 10.1016/j.molcel.2015.01.034 pubmed: 26091343
Ng, E. S., Davis, R., Stanley, E. G. & Elefanty, A. G. A protocol describing the use of a recombinant protein-based, animal product-free medium (APEL) for human embryonic stem cell differentiation as spin embryoid bodies. Nat. Protoc. 3, 768–776 (2008).
pubmed: 18451785 doi: 10.1038/nprot.2008.42
Orlova, V. V. et al. Generation, expansion and functional analysis of endothelial cells and pericytes derived from human pluripotent stem cells. Nat. Protoc. 9, 1514–1531 (2014).
pubmed: 24874816 doi: 10.1038/nprot.2014.102
Feng, Q. et al. Hemangioblastic derivatives from human induced pluripotent stem cells exhibit limited expansion and early senescence. Stem Cells 28, 704–712 (2009).
doi: 10.1002/stem.321
Rufaihah, A. J. et al. Human induced pluripotent stem cell-derived endothelial cells exhibit functional heterogeneity. Am. J. Transl. Res. 5, 21–35 (2013).
pubmed: 23390563 pmcid: 3560482
Crisan, M. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 3, 301–313 (2008).
Kuo, W. L., Meyn, R. E., Haidle, C. W. & Neocarzinostatin-mediated, D. N. A. damage and repair in wild-type and repair-deficient Chinese hamster ovary cells. Cancer Res 44, 1748–1751 (1984).
pubmed: 6231985
Marks, H. et al. The transcriptional and epigenomic foundations of ground state pluripotency. Cell 149, 590–604 (2012).
pubmed: 22541430 pmcid: 3398752 doi: 10.1016/j.cell.2012.03.026
Leitch, H. G. et al. Naive pluripotency is associated with global DNA hypomethylation. Nat. Struct. Mol. Biol. 20, 311–316 (2013).
pubmed: 23416945 pmcid: 3591483 doi: 10.1038/nsmb.2510
Tee, W. W., Shen, S. S., Oksuz, O., Narendra, V. & Reinberg, D. Erk1/2 activity promotes chromatin features and RNAPII phosphorylation at developmental promoters in mouse ESCs. Cell 156, 678–690 (2014).
pubmed: 24529373 pmcid: 4006806 doi: 10.1016/j.cell.2014.01.009
Thornton, S. R., Butty, V. L., Levine, S. S. & Boyer, L. A. Polycomb repressive complex 2 regulates lineage fidelity during embryonic stem cell differentiation. PLoS One 9, e110498 (2014).
pubmed: 25333635 pmcid: 4204901 doi: 10.1371/journal.pone.0110498
Shan, Y. et al. PRC2 specifies ectoderm lineages and maintains pluripotency in primed but not naive ESCs. Nat. Commun. 8, 672 (2017).
pubmed: 28939884 pmcid: 5610324 doi: 10.1038/s41467-017-00668-4
Landeira, D. et al. Jarid2 is a PRC2 component in embryonic stem cells required for multi-lineage differentiation and recruitment of PRC1 and RNA Polymerase II to developmental regulators. Nat. Cell Biol. 12, 618–624 (2010).
pubmed: 20473294 pmcid: 3572404 doi: 10.1038/ncb2065
Fraineau, S. et al. Epigenetic activation of pro-angiogenic signaling pathways in human endothelial progenitors increases vasculogenesis. Stem Cell Rep. 9, 1573–1587 (2017).
doi: 10.1016/j.stemcr.2017.09.009
Yang, Y. et al. Derivation of pluripotent stem cells with in vivo embryonic and extraembryonic potency. Cell 169, 243–257 e225 (2017).
pubmed: 28388409 pmcid: 5679268 doi: 10.1016/j.cell.2017.02.005
Guo, G. et al. Epigenetic resetting of human pluripotency. Development 144, 2748–2763 (2017).
pubmed: 28765214 pmcid: 5560041 doi: 10.1242/dev.146811
Bhardwaj, A., Yang, Y., Ueberheide, B. & Smith, S. Whole proteome analysis of human tankyrase knockout cells reveals targets of tankyrase-mediated degradation. Nat. Commun. 8, 2214 (2017).
pubmed: 29263426 pmcid: 5738441 doi: 10.1038/s41467-017-02363-w
Schneider, R. P. et al. TRF1 is a stem cell marker and is essential for the generation of induced pluripotent stem cells. Nat. Commun. 4, 1946 (2013).
pubmed: 23735977 doi: 10.1038/ncomms2946
De Vos, M. et al. Poly(ADP-ribose) polymerase 1 (PARP1) associates with E3 ubiquitin-protein ligase UHRF1 and modulates UHRF1 biological functions. J. Biol. Chem. 289, 16223–16238 (2014).
pubmed: 24782312 pmcid: 4047392 doi: 10.1074/jbc.M113.527424
Zampieri, M. et al. Parp1 localizes within the Dnmt1 promoter and protects its unmethylated state by its enzymatic activity. PLoS One 4, e4717 (2009).
pubmed: 19262751 pmcid: 2650799 doi: 10.1371/journal.pone.0004717
Vigorelli, V. et al. Abnormal DNA methylation induced by hyperglycemia reduces CXCR 4 gene expression in CD 34(+) Stem Cells. J. Am. Heart Assoc. 8, e010012 (2019).
pubmed: 31018749 pmcid: 6512087 doi: 10.1161/JAHA.118.010012
Liao, Y. et al. NADPH oxidase 4 and endothelial nitric oxide synthase contribute to endothelial dysfunction mediated by histone methylations in metabolic memory. Free Radic. Biol. Med. 115, 383–394 (2018).
pubmed: 29269309 doi: 10.1016/j.freeradbiomed.2017.12.017
Hou, Q., Hu, K., Liu, X., Quan, J. & Liu, Z. HADC regulates the diabetic vascular endothelial dysfunction by targetting MnSOD. Biosci. Rep. 38, BSR20181042 (2018).
Incalza, M. A. et al. Oxidative stress and reactive oxygen species in endothelial dysfunction associated with cardiovascular and metabolic diseases. Vasc. Pharm. 100, 1–19 (2018).
doi: 10.1016/j.vph.2017.05.005
Hammes, H. P. Diabetic retinopathy: hyperglycaemia, oxidative stress and beyond. Diabetologia 61, 29–38 (2018).
pubmed: 28942458 doi: 10.1007/s00125-017-4435-8
Wu, J. et al. Sodium butyrate attenuates diabetes-induced aortic endothelial dysfunction via P300-mediated transcriptional activation of Nrf2. Free Radic. Biol. Med. 124, 454–465 (2018).
pubmed: 29964168 doi: 10.1016/j.freeradbiomed.2018.06.034
Xie, M. Y., Yang, Y., Liu, P., Luo, Y. & Tang, S. B. 5-aza-2'-deoxycytidine in the regulation of antioxidant enzymes in retinal endothelial cells and rat diabetic retina. Int. J. Ophthalmol. 12, 1–7 (2019).
pubmed: 30662833 pmcid: 6326925 doi: 10.18240/ijo.2019.08.19
Carcamo-Orive, I., Huang, N. F., Quertermous, T. & Knowles, J. W. Induced pluripotent stem cell-derived endothelial cells in insulin resistance and metabolic syndrome. Arterioscler Thromb. Vasc. Biol. 37, 2038–2042 (2017).
pubmed: 28729365 pmcid: 5669062 doi: 10.1161/ATVBAHA.117.309291
Chan, X. Y. et al. Three-dimensional vascular network assembly from diabetic patient-derived induced pluripotent stem cells. Arterioscler Thromb. Vasc. Biol. 35, 2677–2685 (2015).
pubmed: 26449749 pmcid: 4603427 doi: 10.1161/ATVBAHA.115.306362
Drawnel, F. M. et al. Disease modeling and phenotypic drug screening for diabetic cardiomyopathy using human induced pluripotent stem cells. Cell Rep. 9, 810–821 (2014).
pubmed: 25437537 doi: 10.1016/j.celrep.2014.09.055
Gu, M. et al. Pravastatin reverses obesity-induced dysfunction of induced pluripotent stem cell-derived endothelial cells via a nitric oxide-dependent mechanism. Eur. Heart J. 36, 806–816 (2015).
pubmed: 25368203 doi: 10.1093/eurheartj/ehu411
Kikuchi, C. et al. Comparison of cardiomyocyte differentiation potential between type 1 diabetic donor- and nondiabetic donor-derived induced pluripotent stem cells. Cell Transpl. 24, 2491–2504 (2015).
doi: 10.3727/096368914X685762
Stepniewski, J. et al. Induced pluripotent stem cells as a model for diabetes investigation. Sci. Rep. 5, 8597 (2015).
pubmed: 25716801 pmcid: 4341212 doi: 10.1038/srep08597
Thatava, T. et al. Intrapatient variations in type 1 diabetes-specific iPS cell differentiation into insulin-producing cells. Mol. Ther. 21, 228–239 (2013).
pubmed: 23183535 doi: 10.1038/mt.2012.245
Kanki, Y. et al. Epigenetically coordinated GATA2 binding is necessary for endothelium-specific endomucin expression. EMBO J. 30, 2582–2595 (2011).
pubmed: 21666600 pmcid: 3155306 doi: 10.1038/emboj.2011.173
Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013).
doi: 10.1093/bioinformatics/bts635
Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
pubmed: 25516281 pmcid: 25516281 doi: 10.1186/s13059-014-0550-8
Subramanian, A. et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545–15550 (2005).
doi: 10.1073/pnas.0506580102
Mootha, V. K. et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetets. Nat. Genet. 34, 267–273 (2003).
Waddington, C. H. The Strategy of the Genes (George Allen & Unwin, London, 1957).

Auteurs

Tea Soon Park (TS)

Institute for Cell Engineering, Department of Oncology, The Johns Hopkins School of Medicine, Baltimore, MD, USA.

Ludovic Zimmerlin (L)

Institute for Cell Engineering, Department of Oncology, The Johns Hopkins School of Medicine, Baltimore, MD, USA.

Rebecca Evans-Moses (R)

Institute for Cell Engineering, Department of Oncology, The Johns Hopkins School of Medicine, Baltimore, MD, USA.

Justin Thomas (J)

Institute for Cell Engineering, Department of Oncology, The Johns Hopkins School of Medicine, Baltimore, MD, USA.

Jeffrey S Huo (JS)

Institute for Cell Engineering, Department of Oncology, The Johns Hopkins School of Medicine, Baltimore, MD, USA.

Riya Kanherkar (R)

Institute for Cell Engineering, Department of Oncology, The Johns Hopkins School of Medicine, Baltimore, MD, USA.

Alice He (A)

Institute for Cell Engineering, Department of Oncology, The Johns Hopkins School of Medicine, Baltimore, MD, USA.

Nensi Ruzgar (N)

Institute for Cell Engineering, Department of Oncology, The Johns Hopkins School of Medicine, Baltimore, MD, USA.

Rhonda Grebe (R)

Wilmer Eye Institute, The Johns Hopkins School of Medicine, Baltimore, MD, USA.

Imran Bhutto (I)

Wilmer Eye Institute, The Johns Hopkins School of Medicine, Baltimore, MD, USA.

Michael Barbato (M)

Institute for Cell Engineering, Department of Oncology, The Johns Hopkins School of Medicine, Baltimore, MD, USA.

Michael A Koldobskiy (MA)

Institute for Cell Engineering, Department of Oncology, The Johns Hopkins School of Medicine, Baltimore, MD, USA.

Gerard Lutty (G)

Wilmer Eye Institute, The Johns Hopkins School of Medicine, Baltimore, MD, USA.

Elias T Zambidis (ET)

Institute for Cell Engineering, Department of Oncology, The Johns Hopkins School of Medicine, Baltimore, MD, USA. ezambid1@jhmi.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH